Compare AKBA & HTBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AKBA | HTBK |
|---|---|---|
| Founded | 2007 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 667.4M |
| IPO Year | 2014 | 1998 |
| Metric | AKBA | HTBK |
|---|---|---|
| Price | $1.60 | $12.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | $6.25 | ★ $12.70 |
| AVG Volume (30 Days) | ★ 2.9M | 1.2M |
| Earning Date | 11-10-2025 | 01-22-2026 |
| Dividend Yield | N/A | ★ 4.33% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.70 |
| Revenue | ★ $225,071,000.00 | $187,676,000.00 |
| Revenue This Year | $52.38 | $13.16 |
| Revenue Next Year | $22.45 | $7.61 |
| P/E Ratio | ★ N/A | $17.16 |
| Revenue Growth | ★ 32.49 | 10.94 |
| 52 Week Low | $1.45 | $8.09 |
| 52 Week High | $4.08 | $12.89 |
| Indicator | AKBA | HTBK |
|---|---|---|
| Relative Strength Index (RSI) | 41.83 | 58.32 |
| Support Level | $1.58 | $11.06 |
| Resistance Level | $1.71 | $12.89 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 16.67 | 20.39 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Heritage Commerce Corp operates as a bank holding company. The company, through its subsidiary, offers commercial banking services to small and medium-sized businesses and their owners, managers, and employees. It operates through two reportable segments, namely Banking and Factoring. A majority of its revenue is generated from the Banking segment, which provides various loan products, including commercial and industrial loans, commercial real estate loans, construction loans, etc. This segment also focuses on deposit generation on relationship accounts, encompassing non-interest bearing demand, interest bearing demand, money market accounts, certificates of deposit, and savings accounts.